In the first quarter of the fiscal year ending December 2026, revenue was 321.7 billion yen (YoY +11.5%), operating income was 158.8 billion yen (YoY +16.2%), and net income attributable to owners of parent was 115.4 billion yen (YoY +18.7%), achieving both higher revenue and profits.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4519","jir_company_name":"Chugai Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-04-24","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/04\/4519-20260424-02.pdf","jir_short_summary":"In the first quarter of the fiscal year ending December 2026, revenue was 321.7 billion yen (YoY +11.5%), operating income was 158.8 billion yen (YoY +16.2%), and net income attributable to owners of parent was 115.4 billion yen (YoY +18.7%), achieving both higher revenue and profits.","jir_summary":"### Performance Overview\nIn the Q1 consolidated financial results for the fiscal year ending December 2026, revenue reached 321.7 billion yen, an 11.5% increase compared to the same period of the previous year. Product sales amounted to 291.6 billion yen (up 12.3% YoY), with domestic sales at 111.4 billion yen (up 8.2% YoY) and overseas sales at 180.1 billion yen (up 14.9% YoY), both showing steady growth. Operating income was 158.8 billion yen (up 16.2% YoY), and net income attributable to owners of parent was 115.4 billion yen (up 18.7% YoY), reflecting earnings growth alongside revenue expansion. The operating margin based on Core results remained high at approximately 50.8%, and R&D expenses accounted for 13.0% of revenue.\n\n### Business Segments and Development Pipeline Status\nOncology sales grew to 55.7 billion yen (up 4.9% YoY) while Specialty segment sales reached 55.7 billion yen (up 11.6% YoY). Overseas sales expanded primarily driven by co-developed products with Roche, especially Hemlibra, whose overseas sales surged to 108.9 billion yen (up 26.3% YoY). Several new drugs in the development pipeline are currently under regulatory review or in Phase III trials, with active progress mainly in oncology and immunology therapeutic areas.","jir_financial_highlights":"Revenue: 321.7 billion yen (YoY +11.5%)\nOperating Income: 158.8 billion yen (YoY +16.2%)\nNet Income Attributable to Owners of Parent: 115.4 billion yen (YoY +18.7%)\nCore EPS: 72.03 yen (YoY +19.5%)\nBasic Quarterly Earnings Per Share: 70.13 yen (YoY +18.7%)\nDividend (Interim): 66 yen (Unknown)","jir_category":"","jir_hashtags":"#ChugaiPharmaceutical, #financial_summary, #JapaneseStocks","jir_key_figures":"Revenue: 321.7 billion yen (YoY +11.5%)\nOperating Income: 158.8 billion yen (YoY +16.2%)\nNet Income Attributable to Owners of Parent: 115.4 billion yen (YoY +18.7%)","jir_meta_title":"Chugai Pharmaceutical Q1 FY2026 Results | Revenue 321.7 Billion Yen (YoY +11.5%), Operating Income 158.8 Billion Yen","jir_meta_description":"Chugai Pharmaceutical\u2019s Q1 consolidated financial results for the fiscal year ending December 2026. Revenue stood at 321.7 billion yen (YoY +11.5%), operating income at 158.8 billion yen (YoY +16.2%), and net income attributable to owners of parent at 115.4 billion yen (YoY +18.7%), achieving growth in both sales and profits.","jir_og_title":"Chugai Pharmaceutical Q1 FY2026 Results | Revenue 321.7 Billion Yen (YoY +11.5%), Operating Income 158.8 Billion Yen","jir_og_description":"Chugai Pharmaceutical reports strong Q1 FY2026 results with higher sales and profits.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend (billion yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025 Q1\\\",\\\"2025 Q2\\\",\\\"2025 Q3\\\",\\\"2025 Q4\\\",\\\"2026 Q1\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[288.5,290.0,333.2,346.3,321.7],\\\"borderColor\\\":\\\"#007bff\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend (billion yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025 Q1\\\",\\\"2025 Q2\\\",\\\"2025 Q3\\\",\\\"2025 Q4\\\",\\\"2026 Q1\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[136.7,136.7,156.5,169.0,158.8],\\\"borderColor\\\":\\\"#28a745\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Income Trend (billion yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025 Q1\\\",\\\"2025 Q2\\\",\\\"2025 Q3\\\",\\\"2025 Q4\\\",\\\"2026 Q1\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income (Attributable to Owners of Parent)\\\",\\\"data\\\":[97.2,97.2,111.2,128.4,115.4],\\\"borderColor\\\":\\\"#dc3545\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Domestic and Overseas Product Sales Trend (billion yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025 Q1\\\",\\\"2026 Q1\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Domestic\\\",\\\"data\\\":[103.0,111.4],\\\"backgroundColor\\\":\\\"#007bff\\\"},{\\\"label\\\":\\\"Overseas\\\",\\\"data\\\":[156.7,180.1],\\\"backgroundColor\\\":\\\"#28a745\\\"}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"core_eps_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Core EPS Trend (yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025 Q1\\\",\\\"2026 Q1\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Core EPS\\\",\\\"data\\\":[60.30,72.03],\\\"borderColor\\\":\\\"#ffc107\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":6836,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-42517","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n